Oral formulation or botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease

Details for Australian Patent Application No. 2003286901 (hide)

Owner Allergan, Inc.

Inventors Barron, Richard L.

Agent Davies Collison Cave

Pub. Number AU-B-2003286901

PCT Number PCT/US2003/0351

PCT Pub. Number WO2004/041303

Priority 10/288,734 05.11.02 US

Filing date 3 November 2003

Wipo publication date 7 June 2004

Acceptance publication date 12 June 2008

International Classifications

A61K 38/48 (2006.01) Medicinal preparations containing peptides

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

Event Publications

1 April 2004 Complete Application Filed

  Priority application(s): 10/288,734 05.11.02 US

1 July 2004 Application Open to Public Inspection

  Published as AU-B-2003286901

12 June 2008 Application Accepted

  Published as AU-B-2003286901

9 October 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003286902-CURABLE PRESSURE SENSITIVE ADHESIVE COMPOSITIONS

2003286900-MODIFIED BROKAW CELL-BASED CIRCUIT FOR GENERATING OUTPUT CURRENT THAT VARIES WITH TEMPERATURE